Origin Life Sciences Aims For $15 Million U.S. IPO

Mar. 15, 2023 3:27 PM ETOrigin Life Sciences, Inc. (OLSI)


  • Origin Life Sciences, Inc. has filed proposed terms for a $15 million U.S. IPO.
  • The firm is developing a medical device for the treatment of various skin and tissue conditions.
  • Given Origin Life Sciences, Inc.'s long road ahead to potential approval and high valuation expectations, I'll pass on the IPO.
  • Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More »

Doctor rebandages mid adult man"s injured foot

SDI Productions/E+ via Getty Images

A Quick Take On Origin Life Sciences, Inc.

Origin Life Sciences, Inc. (OLSI) has filed to raise $15 million in an IPO of its common stock, according to an S-1 registration statement.

The firm is

Global Diabetic Foot Ulcer Treatment Market

Global Diabetic Foot Ulcer Treatment Market (Seeking Alpha)

Statement Of Operations

Statement Of Operations (Seeking Alpha)

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis.

Get started with a free trial!

This article was written by

Donovan Jones profile picture
Leader of IPO Edge
Get IPO Edge with actionable research on next-generation high growth stocks

I'm the founder of IPO Edge on Seeking Alpha, a research service for investors interested in IPOs on US markets. Subscribers receive access to my proprietary research, valuation, data, commentary, opinions, and chat on U.S. IPOs. Join now to get an insider's 'edge' on new issues coming to market, both before and after the IPO. Start with a 14-day Free Trial.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This report is for educational purposes and is not financial, legal, or investment advice. The information referenced or contained herein may change, be in error, become outdated and irrelevant, or be removed at any time without notice. The author is not an investment advisor. You should perform your own research on your particular financial situation before making any decisions. IPO investing can involve significant volatility and risk of loss.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.